USA flag logo/image

An Official Website of the United States Government

Geographically robust rapid assay for T. cruzi infection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60554
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI052683
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Geographically robust rapid assay for T. cruzi infection
Agency: HHS
Contract: 2R44AI052683-02
Award Amount: $849,601.00
 

Abstract:

DESCRIPTION (provided by applicant): This proposal is to develop a rapid serodiagnostic and accurate confirmatory test for detection of Trypanosoma cruzi infections built on a set of novel recombinant antigens. This parasite is transmitted via blood transfusion, is prevalent in Latin America, and is the causative agent for fatal Chagas' disease. Positive blood donors have been identified, and transmission via the insect vector has been reported in the U.S.A. Current methods to detect infection involve serological screening using whole parasites, or crude lysates and confirmation tests in the U.S.A use a complex radioimmunoprecipitation (RIPA) assay. In this proposal, we have used TcF that contains four different repeating epitopes, as the central diagnostic target antigen. We have identified and characterized additional antigens to complement TcF using sera that were non or low reactive with confirmed T. cruzi infection sera. These antigens include recombinants and peptides such as His- 1.1, 1.2, SAPA, Peptide 30 and 36. We will continue to identify additional antigens via serological expression cloning using low titer/RIPA confirmed and TcF low or non-reactive sera from U.S.A. blood donors and from different regions of Central America. This proposal details the development of a rapid inexpensive test for the diagnosis of T.cruzi infections in small clinics/blood banks in Latin America or in diagnosing T. cruzi infections in prospective U.S.A. cardiac surgery patients with high risk factors for Chagas' disease and a confirmatory immunoblot assay for use in the U.S.A blood banks. These studies will exploit the expertise of InBios to develop rapid tests in combination with Corixa TcF antigen. The studies will also benefit from a close collaboration with renowned consultants and collaborators and access to their serum bank.

Principal Investigator:

Syamal X. Raychaudhuri
2063445821
RAYCHAUD@INBIOS.COM

Business Contact:

Syamal Raychaudhuri
2063445821
wendy@inbios.com
Small Business Information at Submission:

INBIOS INTERNATIONAL, INC.
562 1ST AVE. SOUTH, SUITE 600 SEATTLE, WA 98104

EIN/Tax ID: 911791824
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No